Log in to MyACC
General Statement of Disclosure:
CONSULTING FEES/HONORARIA: BCRI(MODEST), Bayer Corporation(SIGNIFICANT), Janssen Pharmaceuticals, Inc(MODEST), Cardiovascular Research Foundation(MODEST), Johnson & Johnson Corp.(SIGNIFICANT), WebMD(MODEST), Gilead Sciences, Inc. (SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Novo Nordisk Inc.(MODEST), Boston Scientific(MODEST), CSL Behring (MODEST), Duke Clinical Research Institute(MODEST), Merck & Co., Inc.(MODEST), Microport(SIGNIFICANT), PERT Consortium(SIGNIFICANT), Somahlution(SIGNIFICANT), CSL Behring (SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), UpToDate in Cardiovascular Medicine (MODEST), Bioclinica(SIGNIFICANT), Daiichi Sankyo(MODEST), Daiichi Sankyo(MODEST), EXCITE International (NONE), Inari(SIGNIFICANT), MashUp MD(MODEST), MashUp MD(MODEST), MD Magazine(MODEST), MD Magazine(MODEST), MJHealth(MODEST), MjHealth(MODEST), Pfizer Inc(MODEST), PhaseBio(SIGNIFICANT), PLxPharma(SIGNIFICANT), PLxPharma(SIGNIFICANT), Revance therapeutics(SIGNIFICANT), Solstic Health/New Amsterdam Pharma(MODEST), Solstic Health/New Amsterdam Pharma(MODEST), Vectura(MODEST), Vectura(MODEST), Woman as one(MODEST), Women as One(MODEST), Angel Medical/Avertix Medical(SIGNIFICANT), Somahlution/Marizyme(SIGNIFICANT), Esperion(SIGNIFICANT), Adaptimmune(MODEST), Beren Therapeutics(MODEST), Beren Therapeutics(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Samsung(SIGNIFICANT), SFJ(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: Fortress Biotech(SIGNIFICANT), Fortress Biotech(SIGNIFICANT), Absolutys(MODEST), Absolutys(MODEST), Dyad Medical(MODEST), Dyad Medical(MODEST) OFFICER, DIRECTOR ETC: Baim Institute (SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Janssen Pharmaceuticals, Inc(SIGNIFICANT), Johnson & Johnson Corp.(SIGNIFICANT), CSL Behring(SIGNIFICANT), Bristol-Myers Squibb Company (NONE), SCAD Alliance(NONE) OTHER FINANCIAL BENEFIT: nference (MODEST)
